Selarsdi, seladelpar
Named-patient access overview. Selarsdi is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
About Selarsdi
Selarsdi (seladelpar) is manufactured by CymaBay (now Gilead), verify and indicated for moderate-to-severe plaque psoriasis in adults and pediatric patients 6 years and older, and active psoriatic arthritis in adults. It is a subcutaneous IL-12 / IL-23 p40-inhibitor biosimilar approved by the US FDA in 2024 and may be accessible to international patients through Named Patient Program or personal-import pathways.
How Reserve Meds coordinates Selarsdi
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Selarsdi for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Selarsdi is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Access by country
Reserve Meds publishes a detailed country deep-dive for Selarsdi in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), real costs in local currency and USD, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.
Start a request for Selarsdi
Submit a 60-second intake. Our clinical team will reach out as our first cohort opens with case-specific feasibility, timeline, and a formal quote.